Medeon Biodesign Receivables

Medeon Biodesign posts a receivables of $54M as of June 2026. That compares with $64M in the prior-year period — down 16.2% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Medeon Biodesign's receivables was $64M. The latest reading is $54M — a 16.2% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Medeon Biodesign's financial statement story. At $54M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 6499.TWO's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Medeon Biodesign's other metric pages and overview cover the third.